Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman(Helen Hayes Hospital), John H. Krege(Eli Lilly (United States)), Karen F. Mauck(WinnMed), Robert A. Wermers(Mayo Clinic), Li Xie(Eli Lilly (United States)), Christopher Recknor(Bone Health and Osteoporosis Foundation), Emmett V. Glass(Eli Lilly (United States))
Cited by 172
Related Papers
Clinician’s Guide to Prevention and Treatment of Osteoporosis
|Osteoporosis International|2014|4.1k
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k
Elevated blood pressures in mice lacking endothelial nitric oxide synthase
|Proceedings of the National Academy of Sciences|1996|903